Letermovir for secondary prophylaxis of CMV infection and disease after allogeneic hematopoietic cell transplantation: Results from the French compassionate program.

Robin, C.; Thiébaut, A.; Alain, S.; Sicre de Fontbrune, F.; Berceanu, A.; D’Aveni, M.; Céballos, P.; Redjoul, R.; Nguyen-quoc, S.; Bénard, N.; Pahlavan-Grumel, Golriz; Cordonnier, C.

doi:10.1016/j.bbmt.2020.01.027

Public

Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.

Shared by NobleBlocks on Feb 5, 2020 • 12:00 AM UTC

Authors:

Robin C

Thiebaut A

Alain S

Abstract

Letermovir potently inhibits the cytomegalovirus (CMV)-terminase complex. Letermovir primary prophylaxis given for the first 3 months after allogeneic hematopoietic cell transplantation (HCT) has been shown to reduce clinically significant CMV infection and is well tolerated. Until now, only case re...

Subject

Cmv Infection

Secondary Prophylaxis

Allogeneic Hematopoietic Cell Transplantation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!